Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2015 07:30 ET | Source: Lisata Therapeutics

PCT, LLC, A Caladrius Company, to Manufacture EU-Compliant Cell Therapy Product for IRX Therapeutics, Inc. From Its New Jersey Facility

ALLENDALE, N.J., Sept. 8, 2015 (GLOBE NEWSWIRE) -- PCT, LLC, A Caladrius Company (PCT), the manufacturing sciences and technical operations subsidiary of cell therapy leader Caladrius Biosciences...
August 06, 2015 16:00 ET | Source: Lisata Therapeutics

Caladrius Biosciences, Inc. Announces Second Quarter 2015 Financial Results and Provides Corporate Update

NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"), a company combining a leading cell therapy service provider with a development...
August 06, 2015 13:47 ET | Source: Lisata Therapeutics

Correction: Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call

NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology and a portfolio of projects...
July 30, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces Second Quarter 2015 Financial Results Conference Call

NEW YORK, July 30, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology and a portfolio of...
July 23, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces NIH Grant to Fund Retinal Disease Research

NEW YORK, July 23, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. ("Caladrius") (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology and a portfolio of...
June 29, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Establishes Cardiovascular Scientific Advisory Board to Support Ongoing Development Efforts Using CD34 Cells

NEW YORK, June 29, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. ("Caladrius" or "the Company") (NASDAQ:CLBS), a cell therapy leader with a Phase 3 clinical program in immuno-oncology—as...
June 23, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces First Patient Dosed in Phase 3 Immunotherapy Trial for Melanoma

NEW YORK, June 23, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today the dosing of the...
June 18, 2015 07:30 ET | Source: Lisata Therapeutics

Caladrius Announces Research Collaboration With the University of Southern California and California Institute of Technology

NEW YORK, June 18, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS), ("Caladrius" or the "Company", formerly NeoStem, Inc.), a cell therapy leader with a late-stage clinical program...
June 15, 2015 06:00 ET | Source: Lisata Therapeutics

PCT, a Caladrius Company, Expands Relationship With ImmunoCellular Therapeutics to Provide Manufacturing For Their Phase 3 Trial

NEW YORK, June 15, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius"), a cell therapy leader with a late-stage clinical program for immuno-oncology, announced today a new...
June 08, 2015 16:01 ET | Source: Lisata Therapeutics

Caladrius Biosciences Issues Letter to Shareholders

NEW YORK, June 8, 2015 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) ("Caladrius" or the "Company"), a cell therapy leader with a late-stage clinical program for immuno-oncology, today...